FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)			1												
Name and Address of Reporting Person * LOBELL J JAY			2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner					
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 2 GANSEVOORT STREET, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 01/01/2021							Office	r (give title belo	ow)	Other (specify b	elow)	
(Street) NEW YORK, NY 10014			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State		(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any		if Co	(Instr. 8)		4. Securities Acquir (A) or Disposed of ((Instr. 3, 4 and 5)		f(D)	Beneficia Reported	nt of Securities ally Owned Following I Transaction(s)		Ownership Form:	Beneficial
				(Month/Day/Year)		Code	V	Amount	(A) or (D)	Price	(Instr. 3 a	(nstr. 3 and 4)		\ /	Ownership (Instr. 4)
Common Stock, par valu \$0.001	o1/0	01/2021				A		100,00	0 A	\$ 0	1,136,000			D	
		Table II - I		tive Secui		Acquir	cont the f ed, Di	ained in orm dis sposed o	this for plays a o f, or Ben	m are currer eficiall	not requ itly valid		formation spond unle trol numbe	ss	1474 (9-02)
Derivative Conversion Date	ansaction hth/Day/Year)	3A. Deemed Execution Date	ite, if	4. Transaction Code (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Unde Secu	tle and ount of erlying rities r. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	Ownershi (Instr. 4)
Security					(In	str. 3,							(instr. 4)	(Instr. 4))

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LOBELL J JAY C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X						

Signatures

/s/ Samuel Berry, Attorney-in-Fact	04/09/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.